Skip to main content

Table 11 Hearing loss at 500 Hz at all time points compared to baseline

From: Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Time point

Treatment

Number

Mean

Std. Dev.

Minimum

Median

Maximum

3 months post-fitting

Placebo

23

29.57

15.88

5.00

25.00

75.00

ACEMg

24

25.00

17.19

− 10.00

25.00

55.00

6 months post-fitting

Placebo

24

31.04

17.69

5.00

27.50

75.00

ACEMg

24

25.83

16.79

− 5.00

25.00

55.00

9 months post-fitting

Placebo

21

33.81

16.50

15.00

30.00

75.00

ACEMg

22

26.82

17.08

− 5.00

25.00

55.00

12 months post-fitting

Placebo

19

33.16

17.34

5.00

30.00

75.00

ACEMg

21

28.57

16.89

5.00

25.00

55.00

  1. The calculation is based on the available measurements at each time point applying the following imputation: If the upper detection limit is reached (110 dB), 120 dB is imputed. Missing values not due to measurement limits are not imputed